Dose Optimization and Efficacy Assessment of a Fluoropyrimidine Antidote

NCT07032142 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Cancer
Toxicity Due to Chemotherapy

Interventions

DRUG: I-01/23

Sponsor

D'Or Institute for Research and Education

Collaborators

[object Object]